Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$35.17 - $68.58
Next Earnings Date
May 06 2025
Next Earnings Date
May 06 2025
Latest price
Market Cap | $3.78B |
EV | $3.72B |
Shares Outstanding | 67.26M |
Beta | 2.32 |
Analyst Rating | BUY |
Analyst Target Price | $78.33 |
P/E 2025E | - |
P/Revenue 2025E | 20.62x |
Revenue | 245.50% |
EPS | -45.80% |
Operating Cash Flow | 8.00% |
Free Cash Flow | 12.50% |
Revenue | 61.10% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 89.70% |
Net Profit Margin 2025E | -92.36% |
ROE 2025E | -403.17% |
ROCE 2024 | -276.33% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Rhythm Pharmaceuticals, Inc.
RYTM
Sector
Healthcare
Industry
Biotechnology
CEO
Meeker, David
Employees
283
Website
rhythmtx.comIPO Date
2017-10-09
Headquarters
222 Berkeley Street, 12th Floor, Boston, Massachusetts, 02116, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved